NasdaqCM:QTTBBiotechs
Can Q32 Bio (QTTB) Justify Its Valuation Following Strong SIGNAL AA Trial Data?
Q32 Bio (QTTB) has completed a $200 million follow on equity offering, shortly after releasing strong 36 week topline data for its bempikibart Phase 2a SIGNAL AA trial in severe alopecia areata.
See our latest analysis for Q32 Bio.
Q32 Bio’s recent bempikibart data and the follow on offering come after a period of sharp share price moves, with the 7 day share price return of 35.54% and year to date share price return of 436.63% pointing to strong momentum. The 1 year total shareholder return...